| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.73▼ | 2.73▼ | 2.74▼ | 2.62▲ | 2.34▲ |
| MA10 | 2.74▼ | 2.74▼ | 2.70▼ | 2.44▲ | 2.24▲ |
| MA20 | 2.74▼ | 2.70▼ | 2.66▲ | 2.24▲ | 2.09▲ |
| MA50 | 2.75▼ | 2.63▲ | 2.52▲ | 2.13▲ | 2.02▲ |
| MA100 | 2.70▼ | 2.51▲ | 2.30▲ | 2.08▲ | 3.18▼ |
| MA200 | 2.65▲ | 2.28▲ | 2.28▲ | 2.03▲ | 5.31▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.004▼ | -0.003▼ | 0.059▲ | 0.082▲ |
| RSI | 37.604▼ | 51.312▲ | 57.023▲ | 71.780▲ | 62.438▲ |
| STOCH | 22.407 | 59.169 | 77.398 | 86.250▲ | 63.443 |
| WILL %R | -100.000▼ | -51.351 | -46.341 | -11.905▲ | -9.174▲ |
| CCI | -232.167▼ | 5.095 | 58.197 | 114.853▲ | 165.489▲ |
|
Friday, February 27, 2026 02:59 AM
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today ...
|
|
Sunday, February 22, 2026 02:15 AM
Nkarta Inc. company and executive profile by Barron's. View the latest NKTX company infomation and executive bios.
|
|
Monday, December 01, 2025 11:09 PM
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/03/26 | 2.69 | 2.79 | 2.60 | 2.69 | 773,806 |
| 27/02/26 | 2.59 | 2.72 | 2.5611 | 2.70 | 678,224 |
| 26/02/26 | 2.60 | 2.65 | 2.48 | 2.62 | 648,365 |
| 25/02/26 | 2.54 | 2.685 | 2.53 | 2.59 | 1,162,644 |
| 24/02/26 | 2.30 | 2.66 | 2.30 | 2.51 | 1,307,776 |
| 23/02/26 | 2.33 | 2.42 | 2.285 | 2.31 | 0 |
| 20/02/26 | 2.33 | 2.36 | 2.28 | 2.33 | 531,561 |
| 19/02/26 | 2.21 | 2.42 | 2.20 | 2.36 | 795,125 |
| 18/02/26 | 2.06 | 2.24 | 2.05 | 2.23 | 641,598 |
| 17/02/26 | 1.99 | 2.105 | 1.975 | 2.06 | 528,188 |
|
|
||||
|
|
||||
|
|